Iovance Historical Income Statement
| IOVA Stock | USD 8.27 0.17 2.10% |
Historical analysis of Iovance Biotherapeutics income statement accounts such as Selling General Administrative of 30.7 M or Other Operating Expenses of 484.8 M can show how well Iovance Biotherapeutics performed in making a profits. Evaluating Iovance Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Iovance Biotherapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Iovance Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iovance Biotherapeutics is a good buy for the upcoming year.
Iovance |
About Iovance Income Statement Analysis
Iovance Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Iovance Biotherapeutics shareholders. The income statement also shows Iovance investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Iovance Biotherapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Iovance Biotherapeutics. It is also known as Iovance Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from Iovance Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Iovance Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.At present, Iovance Biotherapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.6 M, whereas Operating Income is projected to grow to (437.5 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 451K | 3.0M | 11.6M | 12.2M | Interest Income | 451K | 3.0M | 11.6M | 12.2M |
Iovance Biotherapeutics income statement Correlations
Click cells to compare fundamentals
Iovance Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iovance Biotherapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.2M | 1.1M | 14.0M | 21.1M | 33.1M | 34.8M | |
| Selling General Administrative | 40.8M | 60.2M | 83.7M | 104.1M | 27.7M | 30.7M | |
| Other Operating Expenses | 206.9M | 261.9M | 342.7M | 398.9M | 461.7M | 484.8M | |
| Operating Income | (206.9M) | (261.9M) | (342.7M) | (398.9M) | (460.6M) | (437.5M) | |
| Ebit | (206.9M) | (261.9M) | (342.7M) | (398.9M) | (460.6M) | (437.5M) | |
| Ebitda | (205.7M) | (260.8M) | (328.7M) | (377.7M) | (427.4M) | (406.1M) | |
| Total Operating Expenses | 206.9M | 261.9M | 342.7M | 398.9M | 428.6M | 450.1M | |
| Income Before Tax | (197.6M) | (259.6M) | (342.3M) | (395.9M) | (447.5M) | (425.1M) | |
| Net Income | (187.1M) | (257.2M) | (327.8M) | (389.9M) | (444.0M) | (421.8M) | |
| Total Other Income Expense Net | 9.3M | 2.4M | 451K | 3.0M | 13.0M | 13.7M | |
| Income Tax Expense | (10.5M) | (2.4M) | (14.4M) | (6.0M) | (3.5M) | (3.3M) | |
| Gross Profit | (8.1M) | (8.7M) | (14.0M) | (21.1M) | (31.9M) | (30.3M) | |
| Net Income From Continuing Ops | (197.6M) | (259.6M) | (342.3M) | (395.9M) | (433.0M) | (411.3M) | |
| Research Development | 166.0M | 201.7M | 259.0M | 294.8M | 344.1M | 361.3M | |
| Cost Of Revenue | 8.1M | 8.7M | 14.0M | 21.1M | 33.1M | 34.8M | |
| Non Operating Income Net Other | 4.7M | 9.3M | 2.4M | 451K | 518.7K | 492.7K | |
| Net Income Applicable To Common Shares | (197.6M) | (259.6M) | (342.3M) | (395.9M) | (356.3M) | (338.5M) | |
| Interest Income | 9.3M | 2.4M | 451K | 3.0M | 11.6M | 12.2M | |
| Net Interest Income | 9.3M | 2.4M | 451K | 3.0M | 11.6M | 12.2M | |
| Reconciled Depreciation | 1.2M | 1.1M | 14.0M | 21.1M | 29.1M | 30.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Iovance Stock
When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Revenue Per Share 0.008 | Return On Assets (0.34) | Return On Equity (0.67) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.